Lenox Hill Hospital in New York State is revolutionizing radiation oncology treatment with the introduction of the state-of-the-art HyperSight imaging solution. It is the first facility in the state to implement this cutting-edge technology, enhancing precision in targeting malignant tumors while reducing radiation exposure to surrounding tissue. The $5 million investment by Northwell Health demonstrates its commitment to providing the highest quality cancer care. Lenox Hill’s advancements have earned them national recognition for their exceptional cancer treatment programs and surgical expertise.
Lenox Hill Hospital, part of Northwell Health, is making groundbreaking strides in radiation oncology treatment by becoming the first facility in New York State to implement the cutting-edge HyperSight radiotherapy imaging solution. With a significant $5 million investment in radiation oncology, Lenox Hill is elevating its cancer care capabilities.
HyperSight employs state-of-the-art cone-beam computed tomography technology, providing faster and sharper images during radiation therapy. Installed on the hospital’s state-of-the-art Halcyon linear accelerator, this advanced imaging solution enables clinicians to precisely target radiation in cancer patients while minimizing exposure to surrounding organs and tissue. Additionally, HyperSight’s quick six-second image acquisition reduces the need for patients to hold their breath, potentially enhancing their treatment experience and reducing anxiety. These remarkable advancements are part of Northwell Health’s commitment to delivering high-quality, cutting-edge care to cancer patients.
Dr. Louis Potters, chair of radiation medicine at Lenox Hill Hospital and deputy physician-in-chief of the Northwell Health Cancer Institute, expressed enthusiasm for the integration of HyperSight with Halcyon, highlighting its potential to advance the field of radiation oncology significantly. He emphasized that these technological advancements demonstrate Lenox Hill’s unwavering dedication to providing their cancer patients with the highest level of care.
Traditionally, radiation oncologists relied on multiple imaging modalities for image-guided radiation therapy, which often resulted in lower precision and longer procedure times. The advancements in imaging technology now enable clinicians to adjust treatment plans in real-time, based on up-to-date imaging data, thus enhancing the accuracy and effectiveness of therapy.
Developed by Varian, a Siemens Healthineers company, HyperSight features faster image acquisition to reduce motion artifacts, a larger field of view for comprehensive patient anatomy coverage, and advanced reconstruction algorithms to enhance image quality. These enhancements equip healthcare professionals with an innovative tool for the precise targeting of malignant tumors, enabling Lenox Hill clinicians to deliver faster and more accurate care.
External beam radiation therapy plays a vital role in the comprehensive approach to cancer care at the Cancer Institute at Lenox Hill Hospital. This therapy delivers high-dose radiation directly to tumors, effectively damaging their DNA and impeding their growth. As the demand for radiation therapy continues to rise, Lenox Hill is committed to meeting the growing needs of patients by acquiring advanced treatment tools to ensure the delivery of up-to-date care.
Lenox Hill’s exceptional cancer care has earned national recognition, with a top 50 national rating for cancer treatment in 2022-2023 by U.S. News and World Report. The hospital’s colon, lung, prostate, and gynecologic cancer surgery programs have also been designated as “high performing” by the same publication. Additionally, Lenox Hill has been recognized by Healthgrades as one of America’s 100 Best Hospitals for prostate surgery for eight consecutive years. The hospital’s rectal cancer program has achieved a three-year accreditation from the National Accreditation Program for Rectal Cancer (NAPRC), a quality program of the American College of Surgeons Commission on Cancer.
